YONKERS, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), ...

A new class of engineered proteins may counter infection caused by Staphylococcus aureus -- a bacterial species considered one of the largest global health threats, a new study suggests. A new class ...

Linezolid Nosocomial pneumonia, cSSSI Oral and intravenous form available, bacteriostatic, not approved for catheter-related bloodstream infections, side effects include myelosuppression, ...

YONKERS, N.Y., Jan. 10, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), ...

Developers working on methicillin-resistant staphylococcus aureus (MRSA) treatments market are expected to invest resources into research and development activities, for the generation of new product ...

New research could change treatment approaches to simple skin abscesses, infections often caused by Staphylococcus aureus (staph) bacteria. New multicenter research, which included Vanderbilt ...

A National Institutes of Health (NIH)-supported clinical trial has found that the outcome of treating complicated Staphylococcus aureus bloodstream infections with two intravenous (IV) doses of the ...

PHILADELPHIA & SYDNEY--(BUSINESS WIRE)--Clinical stage synthetic cannabinoid company Botanix Pharmaceuticals Limited has today published positive data from a world first human clinical study, ...

Please provide your email address to receive an email when new articles are posted on . Treatment of gram-positive bloodstream infections often is a clinical challenge, especially those caused by ...

As mentioned earlier, there is an urgent need for the development of novel antibiotics targeting S. aureus. Fortunately, a number of new agents active against MRSA and other Gram-positive pathogens ...